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Abstract. Posttraumatic stress disorder (PTSD) is a common and disabling anxiety disorder that may occur in the aftermath of
exposure to potentially traumatic life events. PTSD is moderately heritable, but few specific molecular variants accounting for
this heritability have been identified. Genes regulating the hypothalamic-pituitary-adrenal (HPA) axis, such as corticotrophin-
releasing hormone type 1 receptor gene (CRHR1), have been implicated in traumatic-stress related phenotypes but have yet to
be studied in relation to PTSD. The present study sought to examine the relation between 9 single nucleotide polymorphisms
(SNPs) in the CRHR1 gene and posttraumatic stress symptoms in a prospective study of pediatric injury patients (n = 103) who
were first assessed in the acute aftermath of their injury at the hospital. Results indicated that multiple SNPs were associated
with acute symptoms at a univariate level, and after correction for multiple testing, rs12944712 was significantly related to acute
PTSD symptoms. Longitudinal latent growth curve analyses suggest that rs12944712 is also related to both acute symptom level
and trajectory of symptoms over time. The present study adds support for the role of CRHR1 in the stress response following
potentially traumatic event exposure in youth. It should be noted that the sample size in this study was small, and therefore
statistical power was low; following, results from this study should be considered preliminary. Although results are not definitive,
the findings from this study warrant future replication studies on how variation in this gene relates to response to traumatic event
exposure in youth.
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1. Introduction
Stressful experiences involve the recruitment of the
body’s major stress systems, including the hypothala-
mic-pituitary-adrenal (HPA) axis. The HPA axis, acti-
vated by corticotrophin-releasing hormone (CRH), reg-
ulates the release of stress hormones such as cortisol [1].
In many individuals, this normative stress response is
followed by a return to baseline once the stressor has
passed. However, a subset of individuals evidence al-
terations in this initial stress response and followed by
the chronic dysregulation of the HPA axis characteristic
of traumatic stress related phenotypes, including post-
traumatic stress disorder (PTSD) [2]. There are a num-
ber of key findings suggesting HPA axis dysregulation
that are exhibited in those with PTSD (e.g., elevated
cerebral spinal fluid corticotrophin releasing hormone,
enhanced suppression of cortisol, lower glucocorticoid
receptors in lymphocytes), all of which are consistent
with the notion of a sensitized HPA axis in individuals
with PTSD [for review see 2]. Therefore, there is rea-
son to hypothesize that genes regulating the HPA axis
would be relevant to study in relation to posttraumat-
ic stress symptom trajectory. Notably, however, these
findings suggest that the HPA axis may be dysregulated
in individuals with PTSD, but they are not specific to
PTSD. Many phenotypes are common following expo-
sure to traumatic events, such as depression and oth-
er anxiety disorders, and many of these disorders also
evidence HPA axis dysregulation.
Although there are numerous candidate genes with
potential influence on the HPA axis [3], CRH sys-
tem genes play a critical role in modulation of HPA
stress reactivity [4–7]. As such, these genes may in-
fluence acute and/or chronic alterations in HPA axis
functioning. Although a total of thirty investigations
have examined candidate genes and PTSD [8], only
two studies have examined whether polymorphisms be-
lieved to influence HPA axis functioning are related to
PTSD [9,10], and no prior studies of PTSD have ex-
amined CRH genes. The present investigation exam-
ines the association between nine genetic markers span-
ning the CRH receptor 1 (CRHR1) gene (rs11657992,
rs12936181, rs12944712, rs17690314, rs17763658,
rs242942, rs4074461, rs4458044, rs11657992) and
longitudinal trajectories of PTSD symptoms in pedi-
atric injury patients.
To date, only one study of candidate genes and PTSD
has focused on children [11]. Animal and human stud-
ies support the developmental sensitivity of stress ef-
fects on the HPA axis [12,13]. Indeed, age and develop-
mental stage at the time of the trauma and at the time of
later assessment have been linked to different patterns
of both acute and chronic HPA axis alterations [14,15].
For example, whereas low levels of peritrauma cortisol
predict later development of PTSD in adults [16], high
peritrauma cortisol levels predict subsequent develop-
ment of PTSD in children [17–19]. Interestingly, longi-
tudinal assessments comparing trauma-exposed youth
who did versus did not develop PTSD found that, al-
though acute measures of acute salivary cortisol were
predictive of subsequent development of PTSD (mea-
sured at 1 and 6 months), salivary cortisol levels and
rhythm normalized by 6 months [19]. This pattern of
changing direction in cortisol-PTSD associations was
also found in an investigation of youth assessed within
a year of their trauma compared with youth assessed
more than one year post-trauma [20]; whereas PTSD
symptoms were linearly and positively associated with
cortisol in recently traumatized youth, symptoms were
negatively associated with cortisol in youth whose ex-
periences occurred more than a year prior. These inves-
tigations highlight key considerations for researchers
interested in understanding the relationship between the
HPA axis (as indicated by cortisol) and PTSD: (1) the
association between cortisol and subsequent PTSD dif-
fers in youth and adults and (2) the direction of the as-
sociation between cortisol and PTSD in youth changes
as time since trauma elapses. Thus, while the genetic
predictors of associations between HPA axis function-
ing and PTSD are unknown, it is clear that both age at
time of trauma and duration of time since trauma are
important considerations in traumatic stress research.
Recently, variation in the CRHR1 gene (CRHR1
rs110402 and rs242924) was found to interact with
a history of childhood maltreatment to predict adult
cortisol response to the dexamethasone/CRH test [7];
in both markers, the minor (i.e., less common) alle-
les were found to protect against the effects of child-
hood maltreatment, with maltreated participants ho-
mozygous (GG) for the major allele found to evidence
increased stress reactivity relative to maltreated partici-
pants who were carriers of the minor alleles. This find-
ing was partially replicated in a second investigation of
one of the variants (rs110402), in which the minor al-
lele was associated with decreased cortisol response to
the dexamethasone/CRH test in males, but not females,
reporting childhood trauma [21]. Notably, these effects
were observed in participants with adverse early life
experiences.
Numerous studies of depression provide support for
the CRHR1 gene as a moderator of psychopathology
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following exposure to early life stressors. For example,
Bradley and colleagues (2008) reported an interaction
between genetic markers spanning CRHR1 and child-
hood abuse in prediction of adult depression [22]. Sev-
en out of ten markers spanning the gene showed signif-
icant interactions with childhood abuse in the predic-
tion of depression, with rs110402 and rs7209436 sig-
nificant even after correction for multiple tests. Con-
sistent with prior research, participants experiencing
childhood abuse and possessing the GG rs110402 geno-
type were at greatest risk for depression. Examination
of common haplotypes of CRHR1 revealed a protec-
tive effect of a TAT haplotype formed by three CRHR1
variants (rs7209436, rs110402, rs242924). Providing
even further support for these findings, the results were
replicated with an independent sample that was eth-
nically distinct from the original sample. Polanczyk
and colleagues [23] attempted to replicate and extend
the Bradley et al. investigation using data from two
longitudinal cohort studies. Although findings from
one cohort replicated the protective nature of the TAT
haplotype (rs7209436, rs110402, and rs242924) in the
prediction of depression, results of the second cohort
did not support the expected effects. However both
of these investigations assessed both early life stress
and the psychiatric outcome many years after these ex-
periences, introducing the potential for recall bias and
limiting researchers’ ability to prospectively examine
psychobiological developmental processes in response
to trauma. Additionally, although both depression and
PTSD are stress-sensitive conditions characterized by
alterations of the HPA axis, the patterns of HPA activity
and reactivity found in PTSD diverge markedly from
the patterns found in depression [24].
Although there is considerable theoretical support
for the importance of CRHR1 in the development of
psychopathology following exposure to significant ear-
ly life stress, no extant studies have examined CRHR1
markers in the prediction of PTSD following trauma
exposure during childhood. Indeed, no investigations
to date have examined CRHR1 as related to PTSD in
any sample. Another limitation of extant research is the
absence of studies that examine the influence of genes
on both onset of symptoms and symptom course. As
we have argued elsewhere [25], genes implicated in the
development or onset of symptoms of PTSD may differ
from genes implicated in the maintenance or course
of symptoms of PTSD. Unlike previous cross-sectional
investigations of PTSD candidate genes, the present
investigation involves recruitment and assessment of
participants within hours of trauma exposure followed
by subsequent assessments of symptoms of PTSD at 3
months, 12 months, and 18 months. Thus, the present
investigation can model not only the effects of genotype
at a single time point but also influence of genotype
over time. Consistent with cross-sectional research, we
expected that the minor allele would be protective at the
intercept (within hours of injury). However, as no prior
studies have assessed the influence of candidate genes
on PTSD symptom course, we did not make a priori
hypotheses about the effects of CRHR1 on symptom
course.
2. Methods and materials
2.1. Participants
Participants were 103 children who were sequential-
ly admitted to an inner-city hospital for injuries be-
tween April 2002 and January 2004 [26,27]. All chil-
dren aged 7–18 admitted to the hospital with an injury
were eligible to participate unless they or their parents
did not speak sufficient English to complete the study
instruments, had a Glasgow Coma Scale equal to or less
than 7 at the time of their admission, or lived more than
2 hours away from the hospital (complicating follow up
interviews). Participant characteristics are displayed in
Table 1.
2.2. Enrollment and acute assessment procedure
The families of children who were admitted to the
hospital with an injury were introduced to the study
by a master’s level research associate, once the child
was deemed medically stable by the attending surgeon
(e.g., they did not have a delirium, an active infection
and were not receiving mechanical ventilation). Fami-
lies were told that the study was investigating a child’s
coping following injury. All families were informed
that participation in the study was voluntary and to de-
cline participation would not affect their quality of care.
Written informed consent was obtained from the par-
ents and child after the researcher gave a comprehen-
sive description of the study. The study was approved
by the Institutional Review Board and treatment of hu-
man subjects adhered to established guidelines. The re-
search associate interviewed the child and the primary
caregiver during the initial hospital stay using the psy-
chometric assessment package described below. Every
effort was made to interview the child and caregiver
separately, however the sensitive and complicated na-
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Table 1
Participant characteristics
N (%)/M (S.D.)
Sex
Male 76 (73.8)
Female 27 (26.2)
Age
7–8 8 (7.8)
9–10 7 (6.8)
11–12 9 (8.7)
13–14 11 (10.7)
15–16 31 (30.1)
17–18 37 (35.9)
Self-Reported Race
Non-Hispanic White 42 (40.8)
Non-Hispanic Black 47 (45.6)
Other 14 (13.6)
Injury type
Violent 29 (28.2)
Non-Violent 74 (71.8)
Injury Severity Score 8.91 (6.91)
Number of Days in the Hospital 5.90 (5.78)
Acute UCLA Posttraumatic Stress Disorder Reaction Index 24.09 (12.21)
3-month UCLA Posttraumatic Stress Disorder Reaction Index 21.68 (12.59)
12-month UCLA Posttraumatic Stress Disorder Reaction Index 20.20 (11.60)
18-month UCLA Posttraumatic Stress Disorder Reaction Index 16.85 (10.26)
ture of the hospital stay and setting (e.g., grief, anxiety,
doctor consultations, nurses visits, vitals being taken,
etc.) precluded this in some cases. Each participant
provided a saliva sample using a standard mouthwash
protocol for DNA extraction [28]. Participants were
paid $50 for participation in the acute assessment, and
they were also paid $25 (and transportation costs) to
complete follow-up assessments.
2.3. DNA isolation
Buccal DNA samples were obtained from each sub-
ject via mouthwash. DNA was isolated via standard
procedures using the Gentra DNA isolation kit (Gentra
Systems, Minneapolis MN).
2.4. SNP selection and genotyping
SNP selection was determined using the Phase II
HAPMAP [29]. We used the aggressive tagging op-
tion (2- or 3-haplotype tagging of SNPs) of Tagger
implemented in the program Haploview [30,31]. We
further enriched our SNP selection by including SNPs
implicated in anxiety phenotypes from the published
literature. Genotyping of SNP markers was performed
by mass spectrometry through use of the iPlex as-
say (Sequenom). The major steps in this process in-
cluded the following: primer design using SpectroDE-
SIGNER software; DNA amplification by PCR; post-
amplification removal of the phosphate groups from
the unincorporated dNTPs using shrimp alkaline phos-
photase; primer extension reactions for allele differ-
entiation, salt removal using ion-exchange resin; and
SpectroCHIP plating/analysis by mass spectrometry.
2.5. Outcome measure
Posttraumatic stress symptoms were assessed dur-
ing the acute hospitalization, and at 3-, 12-, and 18-
month follow-ups using the University of California at
Los Angeles Child Post-traumatic Stress Disorder Re-
action Index (UCLA PTSD-RI; [32–34]). The UCLA
PTSD-RI is a 20-item semi-structured interview that
assesses posttraumatic symptoms in children. Children
are asked to rate the frequency of their posttraumatic
symptoms on a 5-point Likert scale from 0 = ”never”
to 4 = ” most of the time”. The measure is most of-
ten used continuously, but a clinical cutoff of 38 can
also be used [34]. The UCLA PTSD RI is internally
consistent, with Cronbach’s alpha in a disaster sample
was reported to be 0.92, and the measure has demon-
strated excellent test-retest reliability (0.84) [35]. The
measure has convergent validity coefficients ranging
from 0.70 (in comparison with the PTSD Module of
the Schedule for Affective Disorders and Schizophre-
nia for School-Age Children) to 0.83 (in comparison
to the Child and Adolescent Version of the Clinician-
administered PTSD Scale). Using a cutoff score of 38,
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sensitivity has been found to be 0.93 and specificity
to be 0.87 in detecting accurate PTSD diagnoses [33].
The UCLA PTSD-RI is one of the most widely used
measures of PTSD symptoms in children [34].
2.6. Covariates
Race/ethnicity information was gathered via self-
report. For analytic purposes, participants were char-
acterized as Non-Hispanic white, non-Hispanic black,
or other. Sex was defined as male or female, and age
at admission was measured in years. Injury Severity
Score (ISS) [36] is a well-validated index of the injury
severity. The ISS is related to the likelihood of survival
after injury and is determined by rating the severity of
injury for six body areas (i.e., head, neck, face, chest,
abdomen, extremity and external) on a five-point scale
known as the abbreviated injury scale (AIS). The AIS
ranges from 1 (minor injury) to 5 (critical injury). The
numerical score represents the degree of life threat as-
sociated with the anatomical injury. The ISS is derived
from the sum of the squares of the AIS score with a
range of 0–75. For patients with multiple traumas the
three most severe injures are squared and summed. A
trained trauma nurse coordinator assigned the ISS score
of the participants in this study. Number of days in the
hospital and whether the participant had experienced a
violent (e.g., was shot, stabbed or physically assault-
ed) versus non-violent injury (e.g., car accident) were
extracted from medical records.
2.7. Statistical analyses
Given the low number of children with probable
PTSD at baseline (n = 18, 17.5%) and at 3-month
follow-up (n = 7, 6.8%) the UCLA PTSD-RI was
used continuously to maximize power. First, single
SNP analyses were conducted in PLINK [37] to deter-
mine if any of the nine SNPs genotyped within CRHR1
were associated at a bivariate level to UCLA PTSD-
RI total score. Also using PLINK, we derived empiri-
cal p-values using permutation tests (10,000 permuta-
tions [38,39]). We adjusted for multiple testing using
a Bonferroni correction.
Finally, the longitudinal influence of CRHR1 rs1294
4712 genotype was modeled using latent growth model-
ing (LGM) in MPlus. Analyses explored linear growth
as well a quadratic slope factor [40]. Parameter esti-
mates were conducted using maximum likelihood esti-
mation with robust standard errors (MLR), which per-
mits application of the missingness option, allowing
retention of all participants on endogenous variables.
Minimum missingness in the present study was 0.33,
suggesting sufficient covariance coverage for a reliable
model [41]. Trajectories of linear time were parame-
terized using months, with the intercept indicated at the
acute in-hospital assessment to permit examination of
the influence of rs12944712 on initial symptom onset.
On the basis of prior research supporting additive pro-
tective effects of the minor allele of rs12944712, the
effects of rs12944712 were modeled in assumption of
an additive genetic effect, with the alleles coded for
symptom risk conferred (i.e., major alleles (G) were
coded to indicate greater “dose,” AA = 0, AG = 1, GG
= 2). To control for potential population stratification
self-reported racial/ethnic status was included as a co-
variate. All analyses also covaried for key individual-
level influences (i.e., age, sex) as well as injury-related
factors (i.e., injury severity, days in hospital, whether
injury was sustained due to violence).
3. Results
3.1. Descriptive analyses
Sample characteristics are presented in Table 1. Par-
ticipants’ racial/ethnic status was reported as: non-
Hispanic white (n = 42, 40.8%), non-Hispanic black
(n = 47, 45.6%), or other (n = 14, 13.6%). In regard
to sex, 73.8% (n = 76) of the participants were male,
and the remaining 26.2% (n = 27) were female. The
average age of participants was 14.63 years (S.D. =
3.18). With regard to injury characteristics, the average
number of days spent in the hospital was 5.90 (S.D. =
5.78). The majority of the injuries were non-violent
in nature (71.8%, n = 74), with the remaining 28.3%
(n = 29) being violent in nature. The average ISS
score was 8.91 (S.D. = 6.91). With regard to UCLA
PTSD-RI scores, the average score was 24.09 (S.D. =
12.21) at the hospital, 21.68 (S.D. = 12.59) at 3-month
follow-up, 20.20(S.D. = 11.60) at 12 month follow-up,
and 16.85 (S.D. = 10.26) at the 18-month follow-up.
Racial/ethnic status was not related to UCLA PTSD-
RI scores at any of the assessment time points, suggest-
ing that even if we did not control for racial/ethnic sta-
tus, population stratification was not a possible cause
of bias in results. Female sex was related to PTSD
symptoms at the acute assessment, 3-month follow-up,
and female sex was marginally related to PTSD symp-
toms at the other follow-up assessments. Age of par-
ticipant was not related to UCLA PTSD-RI total score
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Table 2
List of tested CRHR1 SNPS. Their positions on human chromosome 17, hardy-weinberg equilibrium test p value, minor/major
alleles, minor allele frequency and call rate
dbSNP marker Chromosomal position Hardy-Weinberg p-value Minor/major alleles Minor allele frequency Call rate%
rs4074461 41210922 1.00 G/T 0.48 94.3
rs12944712 41226918 1.00 A/G 0.33 94.3
rs4458044 41229498 0.37 C/G 0.13 93.2
rs12936181 41232250 0.37 C/T 0.22 91.7
rs242942 41247413 1.00 T/G 0.16 94.3
rs17763104 41261576 0.61 A/G 0.12 94.3
rs17690314 41275664 0.35 G/T 0.12 94.3
rs17763658 41278420 0.39 A/G 0.07 94.3
at any time point. In regard to injury characteristics,
violent assaults were related to PTSD-RI score at 12-
and 18-month follow-up assessments. No other injury
characteristics were correlated with UCLA PTSD-RI
score as any time point.
3.2. Genetic analyses
One marker, rs11657992 was excluded from anal-
yses due to its low minor allele frequency (0.0115).
The remaining SNP identifications, their locations,
the Hardy-Weinberg Equilibrium test P – values, mi-
nor/major alleles, minor allele frequencies, and call rate
percentages are shown in Table 2. Call rates for SNPs
ranged from 91 to 95% which included samples that
failed all assays and for which DNA quality was infe-
rior. All SNPs were in Hardy-Weinberg Equilibrium.
The gene encoding CRHR1 is located on chromo-
some 17q21.31 and contains 13 exons spanning 51 kb.
To capture genetic variation across the CRHR1 locus,
we selected a set of 9 SNP located in a 71-kb region
with an average intermarker distance of 9.6-kb (note
that one SNP was removed from analyses). We used
Haploview [30] to determine the LD structure of the
SNPs within the CRHR1 gene which is presented in
Fig. 1. These 8 SNPs capture 46 of the 79 (58%) alle-
les at an R2 > 0.8 using a pair-wise tagging approach
based on the HAPMAP [29] CEPH sample set, and
the SNPs capture 62% of the CRHR1 alleles at an rˆ2
> 0.80 using an aggressive 2- and 3-haplotype. We
identified two different pairs of blocks using the Four
Gamete Rule and the Solid Spine of LD definitions in
Haploview. Of the 103 children from whom we re-
ceived DNA, 4 were removed for low genotyping (<
90%).
3.3. Association analyses
We first conducted single SNP analyses to determine
which markers were associated with UCLA PTSD-RI
score at the acute hospital assessment. As displayed
in Table 3, three SNPs were significantly related to
PTSD symptom frequency (rs4074461, rs12944712,
rs17763104) using empirical p-values. With Bonfer-
roni correction, one of the eight SNPs (rs12944712)
remained significantly associated with PTSD symptom
frequency (see Table 3) and was therefore examined in
the latent growth analysis below.
3.4. Latent growth analyses
The influence of rs12944712 in CRHR1 on the
trajectory of PTSD symptoms was examined us-
ing latent growth curve analysis, controlling for
empirically- and theoretically-determined covariates
including individual-level influences (i.e., age, sex,
race) as well as injury-related factors (i.e., injury severi-
ty, days in hospital, whether injury was sustained due to
violence); all participants with complete data on exoge-
nous variables were retained in this analysis (N = 87).
Using random coefficients regression (Raudenbush and
Bryk, 2002) and maximum likelihood estimation pro-
cedures, a trend for each participant’s symptoms of
PTSD over each time point (in hospital, 3 months, 12
months, and 18 months) was modeled. Participant in-
tercept (acute symptoms of PTSD) and both linear and
quadratic slope (symptoms of PTSD over time) were
predicted by covariates and rs12944712. Estimation
difficulties were encountered in attempts to add non-
linear terms. Findings revealed significant effects of
rs12944712 on both the intercept of acute PTSD symp-
toms as well as the linear slope of PTSD symptoms
over time. Specifically, having an increasing number of
G alleles was significantly associated with more acute
symptoms of PTSD, Estimate = 5.77, SE (Estimate) =
1.43, z-statistic = 3.35, p-value < 0.001. Additionally,
having an increasing number of G alleles was associat-
ed with a significantly greater decline in PTSD symp-
toms over time, Estimate = −0.42, SE (Estimate) =
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Table 3
Single SNP analyses in relation to acute UCLA PTSD-RI score
dbSNP marker β S.E. R2 t Empirical p-value
rs4074461 4.10 1.71 0.06 2.40 0.02
rs12944712 −5.36 1.83 0.08 −2.94 0.005∗
rs4458044 −1.53 2.48 0.004 −0.62 1.00
rs12936181 2.07 2.10 0.01 0.99 0.42
rs242942 −1.00 2.44 0.002 −0.40 0.78
rs17763104 −6.66 2.71 0.07 −2.46 0.02
rs17690314 −5.41 2.89 0.04 −1.87 0.08
rs17763658 3.90 3.27 0.02 1.19 0.26
∗significant after Bonferroni correction (p = 0.05/8 = 0.00625).
Fig. 1. The position of the CRHR1 gene and its exons (filled rectangles) on chromosome 17 as well as a linkage disequilibrium (LD) plot of all
tested SNPs using r2 as the measure of LD.
0.11, z-statistic = −3.74, p-value < 0.001. As shown
in Table 4, female gender was associated with greater
levels of acute PTSD symptoms and having sustained
a violent injury was associated with greater symptoms
of PTSD over time. Unadjusted mean values for these
data are shown in Fig. 2.
4. Discussion
Data reported in this study yielded two main find-
ings. First, results suggest that polymorphisms in the
CRHR1 gene, which is involved in activation of the
HPA pathway, are related to acute PTSD symptoms in
pediatric injury patients. Second, latent growth curve
analyses modeling the trajectory of PTSD symptoms
over time suggest that CRHR1 variation is associat-
ed with both onset and course of PTSD symptoms.
This study is unique in numerous ways; it is not on-
ly the first study to examine CRHR1 variation in re-
lation to PTSD symptoms, but it is also the first lon-
gitudinal examination of genetic variation on PTSD
symptom trajectory. Furthermore, of the 30 candidate
gene studies of PTSD [8], this is only the second study
in which genetic influences on PTSD were examined
in children and adolescents. Specifically, three SNPs
96 A.B. Amstadter et al. / CRHR1 AND PTSD
Table 4
Latent growth curve analysis results
B S.E.(B) B/S.E.(B) StdYX
Intercept
African American 0.26 2.59 0.10 0.02
Other NonWhite 1.59 3.75 0.42 0.07
Age −0.01 0.41 −0.03 −0.01
Days in Hospital −0.18 0.19 −0.93 −0.13
Injury Severity Score 0.26 0.24 1.10 0.22
Violent Injury −1.99 2.17 −0.64 −0.15
Female 6.83 2.81 2.43∗ 0.39
rs12944712 5.77 1.72 3.35∗ 0.52
Slope
African American 0.22 0.17 1.3 0.23
Other NonWhite 0.18 0.20 0.90 0.13
Age 0.02 0.02 1.12 0.15
Days in Hospital 0.03 0.02 1.75 0.36
Injury Severity Score −0.03 0.02 −1.40 −0.31
Violent Injury 0.91 0.27 3.33∗ 0.86
Female 0.13 0.23 0.56 0.86
rs12944712 −0.42 0.11 −3.74∗ −0.58
Note. B = Estimate; SE(B) = standard error of estimate; B/SE(B) = z-
statistic; ∗p < 0.01; StdXY = standardized increase in Y given a standard
deviation increase in X ∗p < 0.01.
Fig. 2. Mean PTSD-RI symptoms by rs12944712 genotype.
(rs4074461, rs12944712, rs17763104) were related to
PTSD symptoms on a univariate level, and after correc-
tion for multiple testing, rs12944712 remained signifi-
cant. For rs1294412, the minor allele (A) was protec-
tive with regard to level of PTSD symptoms reported
at the acute hospital visit, and given that self-reported
race/ethnicity was not related to PTSD symptoms at
any time point, it is unlikely that this was due to issues
related to population stratification.
In contrast to the univariate analysis, the longitu-
dinal analysis controlled for potential individual level
influences (i.e., age, sex, self-reported race/ethnicity)
and injury characteristics (i.e., injury severity, days in
the hospital, whether the injury was violent in nature).
With regard to covariates, elevations in initial PTSD
symptom levels was predicted only by female gender,
which was unrelated to subsequent course of symp-
toms. The only covariate found to significantly pre-
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dict subsequent symptom course was having sustained
a violent injury; youth sustaining injuries secondary to
violence evidenced significantly more symptoms over
time than youth who sustained nonviolent injuries. In-
terestingly, growth analyses revealed significant effects
of rs1294412 on both onset and course of PTSD symp-
toms. Consistent with univariate analyses, the minor
allele of rs1294412 was associated with lower acute
PTSD symptoms, again suggesting a protective effect.
However, interestingly, the major allele (G) was asso-
ciated with a significantly greater decline of symptoms
over time. It is possible that those with the major allele
(G) had higher symptoms acutely and therefore had
more opportunity for a sharper decline over the course
of the study. Alternatively, it is possible that children
exhibiting the most acute distress were also more likely
to receive attention from family and medical personnel
and that this support mitigated symptoms over time.
This is a question we hope to explore in future studies.
Although this is the first examination of CRHR1 ge-
netic variation in relation to PTSD, our findings re-
lated to the degree of PTSD symptoms are general-
ly consistent with previous studies of examining de-
pression in which protective effects of certain CRHR1
SNPs (e.g., rs110402, TAT haplotype) in individuals
with a child abuse history have been reported [42,43].
Our rs12944712 SNP is in strong LD with three of
the four SNPs found to be protective these in prior
reports (rs7209436, rs110402, rs242924). Given that
rs12944712 is an intronic SNP with no known func-
tion, future research is needed to determine if this SNP
is causally related, or if it is just in high LD with a
functional SNP. In other words, the specific biological
mechanism via which the minor allele of rs12944712 in
CRHR1 may be associated with decreased risk of PTSD
symptoms acutely, but be associated with a slower de-
cline in symptoms over time remains to be elucidated.
Although our sample size was too small to fully ex-
amine specific sex effects, previous reports of CRHR1
variation suggest that the genes’ protective effect of
buffering against depression in adulthood in those with
a history of child abuse may be specific to men [21],
however this finding is not universally replicated [43].
The relatively consistent finding across these CRHR1
investigations with our results is rather remarkable, giv-
en the major methodologic differences (e.g., different
SNPs genotyped, all previous papers examined adults,
the majority of traumatic events experienced in the pre-
vious studies were physical or sexual assault). Tak-
en together, these findings point towards relevant poly-
morphisms for stress-related psychopathology in the
CRHR1 gene.
Although the specific functional variants in the
CRHR1 gene and their downstream effects are yet to
be discovered, the biologic relevance of this gene as a
whole to stress-related psychopathology such as PTSD
is clear in light of the key role that CRH has on activat-
ing the HPA axis. Given evidence that PTSD patients
hypersuppress cortisol in response to low-dose dexam-
ethasone treatment [44], models of PTSD development
have been expanded to incorporate altered posttrauma
cortisol response. Yehuda and colleagues proposed
that exaggerated catecholamine increases during trau-
matic stress without the regulatory influence of accom-
panying cortisol increases could lead to inappropriate
memory formation (either over-salient or fragmented
memories) and result in the intrusion symptoms that
characterize PTSD [45]. It is possible that variation in
CRHR1 plays a role in this process, although that is
an empirical question not yet answered. Nonetheless,
the importance of CRHR1 in stress-related pathology
is supported by preclinical and clinical studies [4,5].
4.1. Limitations and future directions
The present data, although unique, are not without
limitations. First, the study was limited by its small
sample size and attrition over the course of follow-up
assessments. Due to the small sample size we were
under-powered to detect small effects, and therefore re-
sults should be considered preliminary. This also lim-
ited our ability to fully examine GxE interactions, pos-
sible developmental specific effects, and possible sex
effects. Further, estimates derived from small samples
may not be stable. Clearly, replication in a larger sam-
ple is warranted. Second, this investigation examined
PTSD symptoms, not a clinical diagnosis of PTSD;
therefore generalization to the PTSD diagnosis may be
limited. Additionally, as noted above, HPA-axis dys-
regulation is not specific to PTSD, which was the only
phenotype examined in the present paper. Future re-
search should also examine CRHR1 variation in rela-
tion to other mood and anxiety disorders. Third, the
results may be confounded by population stratification.
However, genotype distribution did not differ by racial
group and self-reported racial/ethnic status was not re-
lated to PTSD symptoms, so this is unlikely. Fourth,
although 8 SNPs were analyzed, only 58–62% of the
variation in the CRHR1 gene was accounted for. Fu-
ture studies of this gene would be strengthened by fine
mapping and sequencing, thereby allowing for identifi-
cation of functional variants. Lastly, although a stress-
exposed cohort study has advantages, generalizabili-
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ty of the results may be limited as the only traumatic
event category examined in the present study was in-
juries. Future studies should examine a range of trau-
matic event experiences to determine if the findings in
the present study hold.
4.2. Conclusions
Our results suggest that CRHR1 variation is related
to PTSD symptoms in pediatric injury patients, both
acutely, and longitudinally. This is the first longitudinal
genetic association study of PTSD symptoms in chil-
dren that we are aware of that examines gene-symptom
relations within a sample that was recently exposed to
a significant stressor. Furthermore, this is the first ex-
amination of CRHR1 SNPs in association with PTSD
in a trauma-exposed sample, and it is also the second
study to examine PTSD in children and adolescents.
The prospective nature of our study makes our find-
ings less vulnerable to ascertainment or recall biases
than for studies that retrospectively assess adults re-
garding childhood experiences. Results from this study
are not definitive and additional research is needed to
replicate our methodology and findings, but our results
suggest that studying an acutely-exposed hospitalized
sample is both feasible and may improve power to find
gene-disorder associations. Moreover, our findings in
conjunction with data from preclinical models [4] and
the literature on CRHR1 and stress-related pathology
in humans [42,43,46] suggest that this gene is indeed
implicated in the post-trauma trajectory.
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